CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4 Open-market sale VP, Clinical Trial Operations sold 5,200 shares at $19.11 ($99,351)
- 4 Open-market sale Director sold 3,333 shares at an average $20.71 ($69,038)
- 4 Open-market sale VP, Clinical Trial Operations sold 5,200 shares at an average $22.01 ($114,462)
- 4 Open-market sale 10% owner sold 14,251 shares at an average $24.93 ($355,229)
- 4 Open-market sale 10% owner sold 75,690 shares at $25.49 ($1,929,225)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 13,546 shares at an average $24.41 ($330,669)
- 4 Open-market sale 10% owner sold 42,263 shares at an average $24.38 ($1,030,181)
- 4 Open-market sale VP, Clinical Trial Operations sold 5,200 shares at an average $23.56 ($122,528)
- 4 Open-market sale 10% owner sold 16,591 shares at an average $27.85 ($462,001)
- 4 Open-market sale VP, Clinical Trial Operations sold 6,000 shares at $27.96 ($167,786)
- 4 Open-market sale General Counsel sold 10,000 shares at $30.00 ($300,000)
- 4 Open-market sale 10% owner sold 62,459 shares at an average $24.92 ($1,556,591)
- 4 Open-market sale VP, Clinical Trial Operations sold 10,400 shares at an average $21.89 ($227,630)
- 4 Open-market sale Director sold 6,667 shares at an average $23.45 ($156,313)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale VP, Clinical Trial Operations sold 29,800 shares at $21.14 ($629,927)
- 4 Open-market sale 10% owner sold 44,308 shares at an average $21.80 ($965,899)
- 4 Open-market sale Director sold 900 shares at $20.78 ($18,702)
- 4 Grant or award Director acquired 3,460 shares (grant or award)
Page 7 of 10 · 190 filings